Source-linked dosage record
MOUNJARO dose chart
The Eli Lilly prescribing record for MOUNJARO (tirzepatide), organized into a scan-friendly schedule without detaching it from the source document.
- Ingredient
- tirzepatide
- Schedule format
- Label prose rendered as a table
- Label published
- May 06, 2026
- Mirrored
- 2026-08-29
Answer first
Dose schedule
The source publishes the sequence in prose. CareCanon displays that rule as 6 inspectable rows.
| Weeks | Dosage | Phase |
|---|---|---|
| 1 through 4 | 2.5 mg | Starting dosage |
| 5 through 8 | 5 mg | Dose escalation · label-named maintenance option |
| 9 through 12 | 7.5 mg | Dose escalation · label-named maintenance option |
| 13 through 16 | 10 mg | Dose escalation · label-named maintenance option |
| 17 through 20 | 12.5 mg | Dose escalation · label-named maintenance option |
| 21 and onward | 15 mg | Maintenance dosage |
The manufacturer does not publish a titration table for MOUNJARO. The label states the escalation as a rule, quoted below, and the schedule above is that rule set out as a table. No dose has been added, and every dose shown appears in the label’s own “Dosage Forms and Strengths” section.
“The recommended starting dosage is 2.5 mg injected subcutaneously once weekly. After 4 weeks, increase the dosage to 5 mg injected subcutaneously once weekly. If additional glycemic control is needed, increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose.”
Section 3 inventory
Strengths and presentations
This inventory is kept separate from the schedule: a marketed strength is not automatically a starting dose, maintenance dose or recommendation.
Marketed strengths in this brand record
- 2.5 mg
- 5 mg
- 7.5 mg
- 10 mg
- 12.5 mg
- 15 mg
Dosage forms
Injection
Named packages
- Single-dose pen
- Single-dose vial
- Multi-dose vial · 4 doses
- KwikPen · 4 doses
Source excerpt · 3 DOSAGE FORMS AND STRENGTHS
Injection: Clear, colorless to slightly yellow solution in pre-filled single-dose pens, single-dose vials, multi-dose vials, or single-patient-use KwikPens, each available in the following strengths. The multi-dose vials and single-patient-use KwikPen each contain 4 doses: Single-dose Pen or Vial 2.5 mg/0.5 mL 5 mg/0.5 mL 7.5 mg/0.5 mL 10 mg/0.5 mL 12.5 mg/0.5 mL 15 mg/0.5 mL Multi-dose Vial (4 doses per vial) Dose per Injection Total Strength per Total Volume Strength per mL 2.5 mg/0.6 mL 10 mg/2.4 mL 4.17 mg/mL 5 mg/0.6 mL 20 mg/2.4 mL 8.33 mg/mL 7.5 mg/0.6 mL 30 mg/2.4 mL 12.5 mg/mL 10 mg/0.6 mL 40 mg/2.4 mL 16.7 mg/mL 12.5 mg/0.6 mL 50 mg/2.4 mL 20.8 mg/mL 15 mg/0.6 mL 60 mg/2.4 mL 25 mg/mL Single-Patient-Use KwikPen (4 doses per KwikPen) Dose per Injection Total Strength per Total Vol…
Inspect the complete section on DailyMed ↗Source excerpts
What the label says
These excerpts preserve the section names used by the source. Open DailyMed for the complete prescribing information.
2 DOSAGE AND ADMINISTRATION
The recommended starting dosage is 2.5 mg injected subcutaneously once weekly. ( 2.1 ) After 4 weeks, increase to 5 mg injected subcutaneously once weekly. ( 2.1 ) If additional glycemic control is needed, increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose. ( 2.1 ) Maximum dosage ( 2.1 ): Adults: 15 mg subcutaneously once weekly. Pediatric patients 10 years of age and older: 10 mg subcutaneously once weekly. Administer once weekly at any time of day, with or without meals. ( 2.2 ) Inject subcutaneously in the abdomen, thigh, or another person should inject in t…
2.1 Recommended Dosage
The recommended starting dosage of MOUNJARO is 2.5 mg injected subcutaneously once weekly [see Dosage and Administration ( 2.2 )] . Follow the dosage escalation below to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions ( 5.6 ) and Adverse Reactions ( 6.1 )] . The 2.5 mg dosage is for treatment initiation and is not intended for glycemic control. After 4 weeks, increase the dosage to 5 mg injected subcutaneously once weekly. If additional glycemic control is needed, increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose. The maximu…
2.2 Important Administration Instructions
Inform patients and their caregiver(s) which MOUNJARO presentation (e.g., vial, pre-filled single-dose pen, single-patient-use KwikPen) they will receive and ensure they receive training appropriate for that specific presentation. If the prescribed MOUNJARO presentation changes, ensure patients and caregivers receive appropriate training and instruct them to consult the Instructions for Use for the newly prescribed presentation. Prior to initiation, train patients and their caregiver(s) on proper injection technique for the prescribed MOUNJARO presentation [see Instructions for Use] . After tr…
Document history
Recent label changes
Only changes named in the label’s own recent-major-changes block appear here.
| Section | Change | Revised |
|---|---|---|
| 1 | Indications and Usage | 12/2025 |
| 2.1 | Recommended Dosage | 12/2025 |
| 2.2 | Important Administration Instructions | 01/2026 |
| 5.6 | Warnings and Precautions Severe Gastrointestinal Adverse Reactions | 12/2025 |
| 5.10 | Never Share a MOUNJARO KwikPen Between Patients | 01/2026 |
Before using this record
Three useful distinctions
Is this a personal dosing recommendation?
No. It is a reference rendering of prescribing information. A licensed prescriber and pharmacist determine what applies to an individual.
Did the manufacturer publish this exact table?
No. The label states the schedule in prose; CareCanon keeps the source sentence beside the table it renders.
How can I tell whether the source changed?
Use the publication and mirror dates above, inspect the recent-change rows, and open the linked DailyMed record for the current complete document.